We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Metagenomics Enables Rapid Respiratory Infection Testing in ICU Patients

By LabMedica International staff writers
Posted on 28 Feb 2024

Patients with respiratory infectious diseases admitted to intensive care units urgently need appropriate medication, yet microbiologists typically require around three days to identify the responsible pathogens. More...

Now, a new technology could offer a faster diagnostic solution for patients struggling with respiratory infections.

Researchers from Guy’s and St Thomas’ NHS Foundation Trust (GSTT, London, UK) have trialed a new technology that accelerates the genetic testing process for patients with suspected respiratory infectious diseases. This advanced approach, known as metagenomics, sequences genetic material from a comprehensive range of microorganisms, including bacteria, viruses, and fungi, potentially responsible for the infection. Remarkably, results are available in just seven hours, enabling same-day administration of accurate and effective treatments.

Unlike other tests, metagenomic testing can detect all present microorganisms, not limited to those specifically being sought or suspected by clinicians of causing the infection. The researchers have secured additional funding to extend this rapid genetic testing to a broader patient base. This expansion builds upon the initial successful pilot, which demonstrated its potential to enhance treatment for nearly half of the participants. The new funding will facilitate the implementation of this technology in multiple hospitals across the UK over the next two years. The aim is to monitor and curtail the spread of respiratory diseases, ultimately aiding in the prevention of new outbreaks.

“It is vital that the sickest patients in our intensive care unit receive the right medication as quickly as possible,” said Ian Abbs, Chief Executive at Guy’s and St Thomas’ and Co-Chair of the South East Genomic Medicine Service. “This new genetic test can make that happen and we are delighted that we now have funding to ensure other intensive care units, and their patients, can also benefit.”

Related Links:
GSTT


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.